🚀 Portfolio Spotlight: Hera Biotech Endometriosis affects 1 in 10 women globally, yet diagnosis has remained invasive and imprecise—until now. Hera Biotech, one of our FemTech III Fund companies, is revolutionizing diagnostics with MetriDx™, the world's first non-surgical diagnostic for endometriosis. We’re proud to back companies creating solutions that improve lives and expand healthcare innovation. 💙 Want to join the movement of women transforming healthcare? Learn more here: https://lnkd.in/gb58SMYk #WomensHealth #Innovation #Portfolia #FemTech
Very happy for you, Somer Baburek, MBA! Congrats, and keep up the important work!!
Keep shining---Your future is bright! Somer Baburek, MBA
Congrats.
CEO - Hera Biotech - Taking endo diagnosis from surgical to simple
1wThank you for the shout out!!